Try our Advanced Search for more refined results
Life Sciences - August, 2014
307 articles
- $3B Lilly Case Spotlights Drug Promoters' Labeling Quandary
- Ex-Arthrocare CEO Gets 20 Years In $756M Fraud Case
- Texas High Court Won't Overturn Fraudster's Disbarment
- IPO Filings Soar In Late-August Heat
- Sandoz's Remodulin Generic Infringes UTC Patent, Judge Says
- Feds Rip PhRMA's Free Speech Claims In FCA Off-Label Suit
- Takeda Challenges Claim Construction Rule At High Court
- Taxation With Representation: Gibson Dunn, Cravath, Wachtell
- Boston Scientific Wins 2nd Pelvic Mesh Bellwether Trial
- Dealmakers Q&A: WilmerHale's Brian Johnson
- 5 Reasons Large Companies Are Turning To Boutique Firms
- Ebola, ZMapp, And The §101 Guidance
- How To Protect In-House Legal Privilege Internationally
- More Deals Expected This Fall As Economy Pushes M&A Surge
- Takeda, Eli Lilly Stuck With $9B Actos Verdict
- Prestige Must Shed Bonine To Win FTC Nod On $750M Deal
- Apotex Says Generic Paxil Suit Should Be Tossed
- Lannett Faces Shareholder Suit Over Price-Fixing Scheme
- Inventor Fires Back At Patterson Belknap In Surgical IP Row
- Novartis Hits Zydus With Patent Suit Over Dementia Patch
- CMS Gets Heat On Elimination Of Sunshine Act Exemption
- Two More Biotechs Enter IPO Pipeline, One Revives Plans
- Seeking Retrial, Stock Scheme Atty Says Gov't Hid SEC Docs
- Perils Of Communicating With Customers By Phone Or Text
- India Enters The 'Pay-For-Delay' Fray
- 3 Biotechs Join IPO Pipeline, Suggesting Window Still Open
- PhRMA Asks Medicare To Clear Up Sunshine Act Headaches
- The 5 Biggest M&A Moves Of The Summer
- Anda Contradicts Itself In 'Pill Mill' Suit, Insurer Says
- Drugmakers Fight Doc Request In MDL Over Diabetes Drugs
- Skadden Reps JLL Partners-Backed Co. In Biopharma Deal
- Chancery Fast-Tracks Ackman Suit To Force Allergan Meeting
- PhRMA Must Restart Suit Over 340B Orphan Drug Rule
- Philly Mesh Suits Face Uncertainty After Sole Pa. Co. Axed
- Post-AbbVie: Written Description And Functional Claiming
- Allergan Sets Special Meeting In $53B Valeant Takeover Bid
- Salix Investor Challenges $2.7B Inversion Deal With Cosmo
- Appeals Court Nixes Arbitration In Avandia Fee Row
- Virtus, Pamlab Settle Vitamin B False Ad Row In Fla.
- Biotech Co. Zosano Puts IPO Plans On Hold
- Fed. Circ. Told To Nix En Banc Bid In Bristol-Myers IP Case
- FDA Details Stance On Questions From Generics Makers
- Chancery Won't End Astex Buyout Case, Citing Lack Of Notice
- 3rd Circ. Won't Revive Watson Fertility Drug Ad Suit
- Generic Cos. Back On Hook In Reglan Failure-To-Warn Case
- Browne George Gets Arbitration For Sargon Malpractice Suit
- NAFTA Board Tosses $520M Apotex Case Over FDA Import Ban
- Mylan Needn't Recall Generic Precedex In Battle With Hospira
- Pfizer, AstraZeneca Stay Quiet As Cooling-Off Period Ends
- Zimmer Wants Sanctions Against Knee Implant MDL Attorneys
- Teva, AstraZeneca Say Court Rulings Kill Nexium Delay Suit
- Gilead And Potential Unforeseen Consequences: Part 2
- J&J Noncompete Suit On Thin Ice With Worker's Claims Nixed
- Philips Beats Zoll's Challenge To 8 Patents In Fed. Circ.
- Actavis Can't Sell Generic Gralise After Depomed IP Trial
- Virtus Seeks Mistrial In Pamlab's Vitamin B False-Ad Row
- Hospira Rebuts 7th Circ. Rebuke In Worker Retaliation Suit
- Plasma Firms Can't Dodge Calif. Antitrust Claims
- Fresenius Loses Diprivan IP Suit Against Actavis, Dr. Reddy's
- Biotech Co. Preps For IPO, But May Delay Again
- Feds Seek 30 Years In Prison For ArthroCare CEO, 20 For CFO
- Shire Urges High Court Review Of Claim Construction Rule
- Valeant, Ackman Launch Suit Pushing For Allergan Meeting
- Using Post-Grant Proceedings To Challenge Pharma Patents
- 4 Trends In FTC Antitrust Regulation And Enforcement
- Gilead And Potential Unforeseen Consequences: Part 1
- Davis Polk Guides Roche In $8.4B Respiratory Drugmaker Buy
- Judge Won't Toss GSK IP Suit After High Court's Alice Ruling
- Bristol-Myers, Otsuka Hit With Failure-To-Warn Suit For Abilify
- 3 Companies Join IPO Pipeline As Others Take A Step Back
- Corning Doesn't Infringe DSM Fiber Optics Patents, Suit Says
- Sandoz Denied Prosecution Bar In Cardene Patent Row
- Brand Battles: Sherlock Holmes, Seattle Seahawks, The Hobbit
- Fed. Circ. Sides With Generics Makers In Lysteda IP Suits
- Ex-SAC Trader Says 8-Year Sentence Would Be Overly Harsh
- Why AstraZeneca Is Likely On Pfizer's Back Burner, For Now
- Judge Trims Intuitive Surgery Device Securities Class Action
- Transitions Wants Rival's Claims Tossed From Antitrust MDL
- Valeant, Ackman Request Allergan Special Meeting
- FedEx Board Sued Over DOJ Drug Investigation
- Howmedica Sales Reps. Win Cert. In Reimbursement Suit
- Tackling Pot Law A Niche Practice As Some Firms Shy Away
- Dealmakers Q&A: Bird & Bird's Alberto Salvade
- Inter Partes Review's Day Has Come For Pharma IP Cases
- Allergan Suit May Not Stop Meeting To Replace Board
- Purdue Wants Cohen Milstein Atty DQ'd In Chicago Opioid Row
- 1st Circ. Allows FCA Defendants To Push For Tax Breaks
- Whole Foods Slapped With $5M Homeopathy Class Action
- DEA Clamps Down On Hydrocodone Combo Medications
- Deals Rumor Mill: Pfizer, American Tire, VakifBank
- Fed. Circ. OKs AbbVie's Double-Patenting Win In Humira Case
- FDA Approves Covidien's Fixes To Recalled Pipeline Devices
- FDA Unveils Action Plan For Clinical Trial Demographics
- Dr. Reddy's Child-Resistant Drug Packs Under CPSC Scrutiny
- AKS Unlikely To Be Raised Over Pharma Discount Sales
- How To Control Risk And Cost Of E-Discovery
- IP In A Financial Center: Ireland Vs. Cayman Islands
- Inside 2nd Circ. Ruling On Overseas Whistleblower
- Plain Prosecution Bar May Not Cover Inter Partes Reviews
- Fed. Circ. Urged Not To Review Mandate Ruling In $5M IP Row
- Deal Ending $7M Fen-Phen Referral Fee Row May Be Near
- Novartis Gets Zometa Jaw Injury Suit Thrown Out In Calif.
- Deals Rumor Mill: Mylan, Lear, Iliad
- Nexium Buyers Say Ranbaxy Should Turn Over Docs In MDL
- Generic-Drug Consumers Get Rare Boost With Ala. Ruling
- Glenmark Ducks Class Action Over Birth Control Packaging
- 5 Bold Moves Shaping Valeant's Epic Fight For Allergan
- Valeant Says Allergan Lied To Obstruct $53M Takeover
- Mylan Wins Stay Of Generic Precedex Recall In Hospira Row
- Kilpatrick Townsend Adds Life Sciences Partner In Seattle
- 8th Circ. Provides Guidance On FCA Public Disclosure Bar
- Hospira Sues FDA Over Generic Precedex Carve-Out Approval
- Apotex Case Shows Inequitable Conduct Is Still A Potent Tool
- Nautilus Says High Court Indefiniteness Test Kills Biosig Patent
- Tech Cos. Urge High Court To Keep Claim Construction Rule
- FDA Rips Nidek Again On Quality Control Lapses
- High-Profile Fights For Control Showcase Seller's Market
- Allergan Eyes Salix Tie-Up To Thwart $53B Valeant Takeover
- IRS' Med Device Tax Collection Needs Revamp, TIGTA Says
- Apotex's Claim Of Provigil Monopoly To Be Decided At Trial
- AstraZeneca Says DOJ Closing Probe Into Brilinta Trial
- Teva Atty Says He Was Axed Over Family-Support Payments
- Sponsors Should Mind FDA Informed Consent Guidance
- Medtronic Reaffirms $43B Covidien Bid Despite Opposition
- 6th Circ. Revives Aredia Jaw Injury Suit Against Novartis
- FDA Rejects Ex-Staffer's Call To Pull Lasik Devices
- Deals Rumor Mill: Telecom Italia, ConvaTec, SoftBank
- Walgreen Ducks FCA Suit Over Alleged Medicare Overbilling
- IMS Health Rival Can't Duck Poaching Claims In Antitrust Feud
- 6 Tips For FCA Plaintiffs Snubbed By DOJ
- JPML Urged To Ship 28 Cymbalta Suits To California
- Zimmer Protests $79M IRS Transfer Pricing Assessment
- PhRMA Says Integrilin FCA Suit Stifles Free Speech Rights
- Novo Fined For Delaying News Of FDA's Blocking Of Drug
- 2 IPOs Planned This Week As Slow August Continues
- Valeant Giving Allergan Until End Of Year To OK $53B Buyout
- Chugai Denies $10B Roche Takeover Talks
- Fed. Circ. Nixes Apotex Patent For Inequitable Conduct
- MFV Urges High Court To Revive Medtronic Patent Dispute
- Brothers Can't Skirt Insider Trading Verdict Over Chattem Sale
- Gilead Wins Rights To Hep C Drug In Roche Patent Dispute
- Ex-Virginia Gov. McDonnell, Wife Denied Acquittal At Trial
- Deals Rumor Mill: Roche Holding, Arcapita Bank, Shake Shack
- Employee Secrecy Pacts Don't End Whistleblower Threat
- ABL Asks High Court To Let Invalidated Patents Get 2nd Look
- GSK Appeals Mylan Trial Victory Over Generic Paxil Deal
- Generics Lobby Not Fully Sold On FDA Biosimilars Guidance
- Ala. High Court Upholds Landmark Generic-Drug Injury Ruling
- Sen. Durbin Fires Off Inversion-Shaming Letter To Hospira
- CMS Rejects 1/3 Of Sunshine Act Disclosures, Threatens Fines
- UK Clears Cancer Testing Merger On Firm's Financial Woes
- Davita Calls Whistleblowers' FCA Kidney Drugs Suit Flawed
- FedEx Faces Money Laundering Counts In Drug Shipping Case
- Dechert, Mayer Brown Allowed To Collaborate On AIA Reviews
- Valeant Calls Allergan's Insider Trading Claims A Stunt
- An In-House Lawyer's Top 10 Tips For Outside Counsel
- What's More Unnatural Than A Clone?
- Boston Scientific Begins 2nd Mesh Bellwether Trial In Mass.
- Sandoz, Mylan Ask Justices To Affirm Teva Patent Invalidation
- 2nd Circ. Ruling On Overseas Tipsters Dodges Big Issues
- Recall Report: GM, Amgen, McCormick
- FDA Warns Public About Online Ebola Remedy Scams
- Distributor Sues Biz Partner Over FDA Alert, IP Row
- Deals Rumor Mill: Allergan, Electrolux, Axalta
- Medtronic Shakes Most Claims In Bone Device Injury Suit
- Reed Smith Atty's Widow Slams GSK's 'Invasive' Subpoena
- FDA Guides Biologics Makers On Safety Evaluations
- MiMedx Stock Rebound Doesn't Sink Shareholder Suit
- Impax Hit With Investor Class Action After FDA Criticism
- Allergan Makes $588M Acquisition Play Amid Valeant Fight
- Dodd-Frank Doesn't Shield Whistleblowers Overseas: 2nd Circ.
- Dealmakers Q&A: Irell & Manella's Gregory Klein
- Judge Won't Toss SAC Insider Trading Class Action
- Big Data Can Yield Big Insights On Promotional Practices
- Medtronic Ruling Creates Hurdles For Antitrust Defendants
- PhRMA, BIO Open Fire On FDA's Biosimilars Guidance
- SAC Ordered To Hand Over SEC Docs In Insider Trading Suit
- Attorneys Want $3M Fee In Skelaxin Antitrust Row
- FDA Outlines Simpler Approvals For Novel Devices
- FDA Issues Guidance On Unique Device IDs For Small Biz
- SEC Wins Asset Freeze In Pot Stock Pump-And-Dump Case
- Law Firms May Be Violating Copyrights
- 5 Tips For Internal False Claims Act Investigations
- Novak Druce Adds 4 Attys To Houston And Calif. Offices
- Otonomy Raises $100M In Public Debut To Back Ear Treatment
- Dealmakers Q&A: Ungaretti & Harris' Brian Krob
- Dealmakers Q&A: Nixon Peabody's Michele Masucci
- 7th Circ. Warns Attys To Keep Dismissal Bids Spin-Free
- Pfizer Wins Exclusion Of More Experts In Zoloft MDL
- Boston Scientific Atty Fatally Shot, Partner Suspected
- FTC Sends Allergan, Valeant Second Info Request
- Pharmacies Grapple With Surge Of FCA Suits
- Vitamin C Makers, Buyers Fire Closing Salvos In 2nd Circ.
- Drug Developer Geno Ditches IPO Amid Rocky Biotech Market
- Cubist Acquisition Payments Targeted In FCPA Probe
- Ex-Integra Employees Cop To $800K Overbilling Fraud
- J&J Seeks To Boot Suit Claiming Baby Powder Causes Cancer
- Fed. Circ. Won't Reconsider Dolly Clone Patent Ruling
- JPML Won't Centralize Mirena Injury Suits Against Bayer
- JPML Refuses Consolidation Of Endo Birth Control Suits
- AstraZeneca Loses Generic Crestor Challenge In Australia
- Endo, Impax Face Yet Another Suit Over Opana Pay-For-Delay
- Covidien Faces New Investor Suit Over $43B Medtronic Deal
- Vascular Biogenics IPO Undone After Investor Fails To Buy
- Dealmakers Q&A: Gibson Dunn's Stephen Glover
- A Close Look At NY's New Privilege Log Rule
- Hot Boston Legal Market A Boon For Bingham Merger Hopes
- ITC Reverses Burden Of Proof In Sleep-Aid Patent Dispute
- New Bill Floats Sweeping Medicare Fraud Reforms
- Industry Holds Breath As FDA Weighs Remicade Biosimilar
- Forward Pharma Plans $200M IPO To Back Drug Development
- FDA To Allow Vitamin D3 In More Meal Replacement Shakes
- Questcor Must Face Infantile Spasm Drug Antitrust Suit
- Quiet Week Expected With 4 IPOs Amid August Slowdown
- Gilead Wants Finnegan DQ'd In Hepatitis Drug IP Row
- AIA Review Of Wyeth's Tygacil Sought By Drug-Pricing Group
- Pelvic Mesh Part Maker Should Be Freed From Suit, Judge Told
- Taro Settles With Texas For $19.5M Over Medicaid Claims
- Athena Claims Federal Preemption In Eyelash Product Fight
- PharmAthene Wins Damages For Lost Profits In SIGA Row
- Faulty Data Shakes Faith In Sunshine Act Rollout
- McKesson To Pay $18M To End CDC Drug Shipment Claims
- SAC, Cohen Say Investors Unharmed By Alleged Inside Trades
- China Convicts US, British Investigators On Privacy Charges
- NuScience Can't Base IP Suit On One Sale, 9th Circ. Told
- Both Sides Score Evidence Wins In Transvaginal Mesh Case
- Eisai Sues FDA To Reclaim Lost Exclusivity For 2 Drugs
- GSK Paxil Birth Defect Suit Remanded To Calif. State Court
- CVS Looks To Ax False Labeling Suit Over Vitamin E Pills
- $1B Bard Graft Patent War Must End, Gore Tells Fed. Circ.
- Novartis Gets Whistleblower Kickback Suit Pared
- Google To Spend $250M To End Investor Suit Over Pharma Ads
- How Pot Businesses Can Make Your Property Go Up In Smoke
- FTC V. Cephalon — The Actavis Fray Begins
- Compliance Reigns Supreme As In-House Demographics Shift
- Divisive IP Ruling May Mean New Antitrust Liability — Or Not
- Illumina Can't Dodge Ariosa Counterclaims In DNA Test Fight
- Reckitt Stiffed Us On Mucinex Supply Deal, Generic Cos. Say
- 6th Circ. Says Stryker Owes Insurer $2M In Bad Knee Row
- Becton Says Fed. Circ. Misapplied 'Mandate Rule'
- CMS Extends Window For Sunshine Act Pay Verification
- Brazil Fines Merck $1.8M Over Plot To Block Generics
- New FDA Rules Are Boon To Medical Mobile App Developers
- Fidelity Dumps Valeant Shares In Thick Of Allergan Assault
- Roxane Loses Bid To Block Hetero's Generic Kidney Drug
- Public Reports Save Stryker From FCA Suit At 8th Circ.
- FTC Seeks More Docs From Medtronic Over $42B Covidien Buy
- Biotech IPO Market Wavers As 2 Postpone, 1 Falls Short
- Collaboration In The Shadow Of The Billable Hour
- K&L Gates Nabs Ex-Baker & McKenzie Life Sci, M&A Pro
- Lot Of Inversion Talk, But Do You Know The Basics?
- St. Jude's, Amgen Settle Cancer Research Patent Row
- US Attorney Questions Boston Scientific's BridgePoint Buy
- Shire Seeks To Ax Adderall Antitrust Class Action In Fla.
- IG Flags $32M Paid By Medicare In Suspect HIV Drug Sales
- Fed. Circ. Revives Patent Antitrust Claims Against Tyco
- Most Of Med Device Sales Trade Secrets Suit Survives
- Mich. High Court Buries CVS, Rite Aid Generics FCA Suits
- Fed. Circ. Revives ScriptPro Pill-Dispenser Patent Suit
- Target, Pfizer, Others Voice Support For Gay Marriage
- Proxy Advisers Slam Allergan, Support Shareholder Meeting
- Galderma Sued Over Patent Sale Agreement For Skin Drug
- Abbott Won't Appeal 9th Circ. Gay Juror Decision in GSK Row
- NAD Snuffs Merck's Objections To Sanofi Nasal Spray Claims
- 2nd Circ. Throws Out Appeal Of Lipitor FCA Dismissal
- NuVasive Can't Duck $30M Verdict In Neurovision TM Row
- Pfizer Pays $35M To Settle AGs' Rapamune Marketing Probe
- Class Cert. Denied In TCPA Suit Against Medtox Scientific
- Feds Charge Biogenesis Exec, Others In MLB Doping Scandal
- 10th Circ. Revives Medtronic Bone Mill Antitrust Case
- Stock Pushers Charged After SEC Pot Pump-And-Dump Probe
- Ex-Manager For NJ Pharma Co. Accused Of Embezzlement
- FDA Outlines Distinct Risks Of At-Home Medical Devices
- AMA, Medical Groups Decry Sunshine Act Database Launch
- Takeda Barred From Doubling Up Patent Claims In Drug Case
- Class Action Atty On Hook For $42M Fen-Phen Judgment
- Allergan's Valeant Suit Could Be Landmark Securities Case
- Norton Rose Fulbright Survives DQ Bid In Pamlab Suit
- AOPA Suit Over Medicare Prosthetics Payment Rule Tossed
- Auris Medical Cuts Expected IPO To $56M
- Allergan Continues Assault On Valeant Disclosure Policy
- 5 Takeaways From FDA Medical Device Data System Guidance
- Baby Sex Prediction Co. Tells 9th Circ. Calif.'s Suit Is Barred
- CORRECTED: NuVasive Seeks New Trial In Bid To Nix $30M IP Verdict
- Roche Win Upheld In 'Twin Peaks' Star's Accutane Case
- 9th Circ. Keeps Fentanyl Death Suit In Federal Court
- FTC OK's $324M Akorn Deal For Drugmaker, With Conditions
- Deals Rumor Mill: TPG, Gables, GlaxoSmithKline
- 'Sugar Pill' Buyers Win Class Cert. In Homeopathy Suit
- Kromann Advises Roche On $450M Santaris Buy
- FDA Set To Release Biosimilars Naming Guidance, Sens. Say
- Puritan's Pride Prevails In Tissue Regeneration Patent Brawl
- Medical Device Equivalence Analysis Examines 2 Factors
- Verein Tie-Ups Gain Allure As Firms Eye Global Expansion
- UK Firms Expand Global Empire, But US Firms Gaining Ground
- Law360's Global 20 Firms Take Global To New Heights
- SmartGene Says IP More Abstract Than Alice, Mayo Claims
- USPTO Warned New Eligibility Rules Put Patents At Risk
- Novak Druce Expands To Philly With Blank Rome IP Atty
- Fed. Circ. Nixes Rehearing Bids In Colon Cleanser Patent Row
- McKenna Long Loses Bid For Sanctions In Malpractice Row
- Aruba Networks Exec Has Plan To Limit Patent Bill To Trolls
- Deals Rumor Mill: CorePharma, Awas, SMBC
- AstraZeneca Sues Zydus To Block Generic Nexium
- Allergan Alleges Insider Trading Between Valeant, Ackman
- FDA Frees Wide Range Of Devices From Oversight
- Canadian Limits On Cooperation With Foreign Courts